Provinciali Mauro, Smorlesi Arianna, Donnini Alessia, Bartozzi Beatrice, Amici Augusto
Laboratory of Tumor Immunology, INRCA Gerontology Research Department, Immunology Centre, Via Birarelli 8, 60121 Ancona, Italy.
Vaccine. 2003 Feb 14;21(9-10):843-8. doi: 10.1016/s0264-410x(02)00530-3.
We evaluated the effectiveness of vaccination with a HER-2/neu DNA plasmid to induce protective immunity against HER-2/neu overexpressing syngeneic TUBO tumour cells in old ages. Young and old Balb/c mice received three immunizations with a pCMVneuNT DNA plasmid and, successively, were challenged with TUBO cells. Young mice were completely protected whereas less than 60% protection was observed in old mice. Anti-p185(neu) antibodies were found in the sera from both young and old immunized mice, even if antibody production was significantly higher in young in comparison with old mice. Similarly, higher anti-p185(neu) lymphocyte proliferation was induced in young than in old mice. No anti-p185(neu) cytotoxicity was found in lymphocytes from old animals. We conclude that anticancer DNA vaccination has a lower effectiveness in old than in young ages.
我们评估了用HER-2/neu DNA质粒进行疫苗接种,以诱导针对老年时HER-2/neu过表达的同基因TUBO肿瘤细胞产生保护性免疫的效果。年轻和年老的Balb/c小鼠用pCMVneuNT DNA质粒进行三次免疫接种,随后用TUBO细胞进行攻击。年轻小鼠得到完全保护,而老年小鼠的保护率不到60%。在年轻和年老的免疫小鼠血清中均发现抗p185(neu)抗体,尽管年轻小鼠的抗体产生量明显高于老年小鼠。同样,年轻小鼠诱导产生的抗p185(neu)淋巴细胞增殖高于老年小鼠。在老年动物的淋巴细胞中未发现抗p185(neu)细胞毒性。我们得出结论,抗癌DNA疫苗接种在老年时的效果低于年轻时期。